Animal-Derived Supplements
The first MAb was produced over thirty years ago, in 1975 by Milstein and Köhler. Since then, the cell culture market has been optimizing these cell lines for use in the production of therapeutic proteins. The CHO (Chinese hamster ovary) cell line is the most common mammalian cell line successfully developed for the production of therapeutic proteins.
The overarching benefit of using mammalian cell culture is the creation of a protein with many of the characteristics and the structure of the natural protein, therefore providing better end-functionality and reducing the possibility of adverse immunological reactions. Mammalian cell lines also offer the opportunity for post-translational modification of the resultant protein, such as via glycosylation.
Despite their many advantages, mammalian cells are among the most complex to work with from a bioprocessing perspective. Even though they are produced in lower amounts, their processing and scale-up parameters can be more complex and include:
- Supplementation requirements
- Controlled feeding strategy
- Advanced and complex media needs
Animal-derived supplements provided the first, and in many cases still the standard, for supplementation. Our animal-derived supplement portfolio is used globally in both diagnostics and in numerous commercial biopharmaceutical products.
Novidades sobre Produtos e Releases
- 2009年2月： Prep/Scale®製品の包装変更、即時実施についてのご案内
- 2009年1月：Biomax®1000kD（PBXK）、500kD（PBVK）および300 kD（PBMK）メンブレンを含むPellicon®2及びPellicon XLの適格性確認に関するお知らせ（2009年4月実施）
- 2008年11月：ジェファリー工場で製造している100kDまでのBiomax®メンブレンを使用した Pellicon®XLカセットの適格性確認に関するお知らせ
- 2008年9月：ガンマ滅菌済みMillipak®(ミリパック)フィルター製品の包装変更について
- 2007年9月: Durapore®, Aervent®, Optiseal®, 及びMillipore Express®カートリッジ、並びに、Millipak®、Millidisk®、Opticap®カプセル製品の品質証明書中の試験名称変更のお知らせ
- Millipore Unveils Single-Use Mobius CellReady 3L Bioreactor at ESACT Meeting
Featured Products
